Dr. Jason R Williams

Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute. | Author of “The Immunotherapy Revolution”

Overview And

Jason Russell Williams (born April 8, 1974) is an American Radiologist and Interventional Oncologist specializing in image-guided procedures for cancer and immunotherapy. He is considered a pioneer in intratumoral immunotherapy and cancer ablative technologies such as cryoablation and RFA. He is involved in research with immunotherapy drug development and image-guided devices to treat cancer.

He was the winner of the 2019 Vince Lombardi “Leaders for a Cure Award.” He has won 2007 Telly and Communicator awards for his video work on RFA. He won the RSNA (Radiological Society of North America) Research fellow award in 2004. He is an American board-certified radiologist and author of “The Immunotherapy Revolution, The Best New Hope for Saving Cancer Patients’ Lives.” He is the founder of Williams Cancer Institute and an adjunct professor at Case Western Reserve University.




Jason Russell Williams
April 8, 1974 (Age 48)
Hattiesburg, Mississippi, U.S.


Louisiana State University Health Sciences Center, Medical Doctorate (2000)

University of South Alabama, Internship Internal Medicine

University of South Alabama, Residency Radiology (2007)

Southeastern Louisiana University, Chemistry (1996)

Known for

Intratumoral immunotherapy

Best-selling author of the book “Immunotherapy Revolution, The Best New Hope For Saving Cancer Patients’ Lives”

Image-guided ablation


Dr. Williams focuses on image-guided ablative technologies, including RFA, cryoablation, and microwave ablation. He is also working on other ablative technologies and liquid injectables with ablative and immune-stimulating properties. He also focuses on multiple combination injections of immunotherapy agents, which led him to be a co-founder of a biotech, Syncromune.

One of his main research areas is using technology such as NanoString and IHC to evaluate the tumor microenvironment to develop adaptive combinations of immunotherapy injected into the tumor to respond to the cancer’s treatment adaption and immune resistance. He also has founded a company, Cancer Care AI, that uses Artificial intelligence technology to predict supplements, targeted and off-label drugs that may enhance immunotherapy response rates. He also continues to maintain an interest in gene therapy.

● Combined use of image guided ablation with immune checkpoint inhibitors, Ipilimumab and Nivolumab (anti CTLA-4 and PD-1).

● Intra-tumoral Toll-like receptor agonist (TLR) imiquimod and CpG combined with Cryoablation and immune checkpoint inhibitors.

● Intra-tumoral PV-10 combined with cryoablation and AblationVax.

● Implantable IDO inhibitor pellet (Indoximod) combined with Cryoablation and immune checkpoint inhibitors.

● Intra-arterial 3-bromopyruvate combined with intra-arterial immune checkpoint
inhibitors Ipilimumab and Nivolumab.
● Intra-arterial hepatic infusion of immunotherapy, Nivolumab and Ipilimumab.

● Cryoablation of cancer combined with intra-tumoral injection of Montanide.

Early Life

On April 8, 1974, Williams was born in Hattiesburg, Mississippi, to Lois and James G. Williams. His father taught at Hinds Community College, and his mother was a nurse. At the age of 10, the family relocated to Madisonville, Louisiana, to be close to his grandmother, who had been diagnosed with breast cancer. The difficult process he witnessed with his grandmother, and ultimately her passing when he was age 12 led him into cancer. While in college studying chemistry, he joined a summer program that put him in the lab of Julie Cook, Ph.D. He studied gene therapy for cancer in this lab, mainly focusing on p53.

He noted the excellent results when treatments were injected into tumors but lacked when used systemically, such as oral or IV. After he was accepted directly into medical school before graduating from college. In medical school, he learned of the specialty of interventional radiology and its ability to biopsy tumors with image guidance. It inspired him that it was possible for humans to inject medications into tumors in the same way he witnessed success in animal studies. He earned his doctorate in medicine from Louisiana State University Health Sciences Center, Shreveport, LA, in 2000.


Medical School: Louisiana State University Health Sciences Center.

Internship: Internal Medicine, University South Alabama.

Medical School: Louisiana State University Health Sciences Center.

● Medical School: Louisiana State University Health Sciences Center.

● Internship: Internal Medicine, University South Alabama.

● Radiological Society of North America Resident/Fellow of the year award 2002.
● 2007 Telly award.

First in procedures

●Breast ablation
●Breast ablation

●First in human, intratumoral 3-Bromopyruvate
●First in human, combination intratumoral Yervoy/Opdivo with tumor ablation
●First in human, intratumoral combination Yervoy/Opdivo/CpG/PV-10

●First in human, intra-arterial infusion into liver tumors, a combination Yervoy/Opdivo
●First in human, intratumoral OX40/CpG agonist

Immunotherapy: The only solution for the fight against cancer.